Dicerna Pharmaceuticals Stock News

Sumitomo Mitsui Trust Holdings Inc. lessened its position in shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) by 94.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 23,901 shares of the biopharmaceutical companys stock after selling 432,596 shares during the quarter. Sumitomo Mitsui Trust Holdings []

Equities analysts forecast that Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) will report earnings of ($0.44) per share for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Dicerna Pharmaceuticals earnings. The highest EPS estimate is ($0.04) and the lowest is ($0.99). Dicerna Pharmaceuticals reported earnings per share of ($0.49) during the same quarter last []

The trading price of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) floating lower at last check on Wednesday, December 15, trading at $37.91, 0.00% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) have been assigned an average recommendation of Hold from the twelve ratings firms that are covering the company, MarketBeat reports. Ten analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12 month target price among brokers that []

Shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) have been given an average recommendation of Hold by the twelve brokerages that are currently covering the firm, MarketBeat.com reports. Ten analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have []

Chardan Capital lowered shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) from a buy rating to a neutral rating in a research report report published on Wednesday morning, The Fly reports. They currently have $38.25 price target on the biopharmaceutical companys stock, up from their prior price target of $28.00. A number of other equities research analysts have []

Dicerna Pharmaceuticals Inc

Brokerages expect that Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) will announce earnings per share (EPS) of ($0.44) for the current quarter, according to Zacks. Four analysts have made estimates for Dicerna Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.99) and the highest estimate coming in at ($0.04). Dicerna Pharmaceuticals posted earnings of ($0.49) per []

Vigilare Wealth Management increased its holdings in shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) by 163.0% in the third quarter, HoldingsChannel reports. The firm owned 19,200 shares of the biopharmaceutical companys stock after buying an additional 11,900 shares during the period. Vigilare Wealth Managements holdings in Dicerna Pharmaceuticals were worth $387,000 as of its most recent []

Brokerages forecast that Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) will post sales of $60.28 million for the current quarter, Zacks reports. Four analysts have provided estimates for Dicerna Pharmaceuticals earnings, with the highest sales estimate coming in at $92.60 million and the lowest estimate coming in at $31.00 million. Dicerna Pharmaceuticals reported sales of $40.96 million in []

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) has a beta value of 0.99 and has seen 3.48 million shares traded in the recent trading session. The company, currently valued at $2.97B, closed the recent trade at $37.99 per share which meant it lost $0.0 on the day or 0.01% during that session. The DRNA stock price is -5.66% Dicerna Pharmaceuticals Inc. (DRNA) Has Strong Growth Prospects Through 2021 Read More »

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) shares saw an uptick in trading volume on Monday . 52,728 shares changed hands during trading, a decline of 95% from the previous sessions volume of 1,136,975 shares.The stock last traded at $38.00 and had previously closed at $37.99. A number of brokerages have issued reports on DRNA. Stifel Nicolaus lowered []

SVB Leerink restated their buy rating on shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) in a research note published on Thursday, Analyst Price Targets reports. Other analysts have also recently issued research reports about the company. Citigroup cut Dicerna Pharmaceuticals from a buy rating to a neutral rating and set a $32.00 target price on the stock. []